These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21362762)

  • 1. Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis.
    Wang SY; Liu YY; Ye H; Guo JP; Li R; Liu X; Li ZG
    J Rheumatol; 2011 May; 38(5):821-7. PubMed ID: 21362762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Dickkopf-1 and osteoprotegerin in patients with early and longstanding rheumatoid arthritis.
    Liu YY; Long L; Wang SY; Guo JP; Ye H; Cui LF; Yuan GH; Li ZG
    Chin Med J (Engl); 2010 Jun; 123(11):1407-12. PubMed ID: 20819596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.
    Buch MH; Bingham SJ; Seto Y; McGonagle D; Bejarano V; White J; Emery P
    Arthritis Rheum; 2004 Mar; 50(3):725-8. PubMed ID: 15022311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
    J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response.
    Marotte H; Maslinski W; Miossec P
    Arthritis Res Ther; 2005; 7(1):R149-55. PubMed ID: 15642135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.
    Daoussis D; Liossis SN; Solomou EE; Tsanaktsi A; Bounia K; Karampetsou M; Yiannopoulos G; Andonopoulos AP
    Arthritis Rheum; 2010 Jan; 62(1):150-8. PubMed ID: 20039407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis.
    Gengenbacher M; Sebald HJ; Villiger PM; Hofstetter W; Seitz M
    Ann Rheum Dis; 2008 May; 67(5):620-4. PubMed ID: 17720725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
    Marotte H; Arnaud B; Diasparra J; Zrioual S; Miossec P
    Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
    Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
    Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
    J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
    Seitz M; Zwicker M; Villiger PM
    J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
    Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber NJ
    J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis.
    Steiner G; Studnicka-Benke A; Witzmann G; Höfler E; Smolen J
    J Rheumatol; 1995 Mar; 22(3):406-12. PubMed ID: 7783054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis.
    Kopp S; Alstergren P; Ernestam S; Nordahl S; Bratt J
    Scand J Rheumatol; 2006; 35(3):182-8. PubMed ID: 16766364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.